
Benoit You

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3917334/publications.pdf Version: 2024-02-01



RENOIT YOU

#	Article	IF	CITATIONS
1	Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. New England Journal of Medicine, 2019, 381, 2416-2428.	27.0	1,176
2	Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncology, The, 2020, 21, 1155-1164.	10.7	274
3	The official French guidelines to protect patients with cancer against SARS-CoV-2 infection. Lancet Oncology, The, 2020, 21, 619-621.	10.7	155
4	A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors. International Journal of Cancer, 2019, 145, 639-648.	5.1	151
5	Pathological Response to Neoadjuvant Chemotherapy: A New Prognosis Tool for the Curative Management of Peritoneal Colorectal Carcinomatosis. Annals of Surgical Oncology, 2014, 21, 2608-2614.	1.5	116
6	A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <i>PIK3CA</i> -Mutated Breast and Gynecologic Cancers. Clinical Cancer Research, 2018, 24, 2050-2059.	7.0	96
7	Assumptions of Expected Benefits in Randomized Phase III Trials Evaluating Systemic Treatments for Cancer. Journal of the National Cancer Institute, 2012, 104, 590-598.	6.3	94
8	Progression Following Neoadjuvant Systemic Chemotherapy May Not Be a Contraindication to a Curative Approach for Colorectal Carcinomatosis. Annals of Surgery, 2012, 256, 125-129.	4.2	90
9	Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial. Nature Medicine, 2021, 27, 250-255.	30.7	85
10	Quality of Reporting of Modern Randomized Controlled Trials in Medical Oncology: A Systematic Review. Journal of the National Cancer Institute, 2012, 104, 982-989.	6.3	83
11	Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial. Journal of Clinical Oncology, 2020, 38, 3129-3137.	1.6	66
12	Hypersensitivity to oxaliplatin: clinical features and risk factors. BMC Pharmacology & Toxicology, 2014, 15, 1.	2.4	60
13	Practical clinical guidelines of the EOTTD for treatment and referral of gestational trophoblastic disease. European Journal of Cancer, 2020, 130, 228-240.	2.8	58
14	Mortality rate of gestational trophoblastic neoplasia with a FIGO score of ≥13. American Journal of Obstetrics and Gynecology, 2016, 214, 390.e1-390.e8.	1.3	56
15	First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers. British Journal of Cancer, 2017, 116, 1126-1134.	6.4	55
16	CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial. Clinical Cancer Research, 2020, 26, 4625-4632.	7.0	47
17	Antiâ€EGFR Monoclonal Antibodies for Treatment of Colorectal Cancers: Development of Cetuximab and Panitumumab. Journal of Clinical Pharmacology, 2012, 52, 128-155.	2.0	46
18	A Phase II Trial of Erlotinib as Maintenance Treatment After Gemcitabine Plus Platinum-based Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 255-260.	1.3	45

#	Article	IF	CITATIONS
19	Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2012, 18, 1743-1750.	7.0	45
20	Etoposide pharmacokinetics and survival in patients with small cell lung cancer: A multicentre study. Lung Cancer, 2008, 62, 261-272.	2.0	37
21	The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: Data from CALYPSO trial (a CINECO-GCIG study). Gynecologic Oncology, 2013, 130, 289-294.	1.4	34
22	Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements. British Journal of Cancer, 2013, 108, 1810-1816.	6.4	34
23	Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study. Clinical Cancer Research, 2019, 25, 5342-5350.	7.0	33
24	Trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial Journal of Clinical Oncology, 2021, 39, 526-526.	1.6	32
25	Contribution of modelling chemotherapy-induced hematological toxicity for clinical practice. Critical Reviews in Oncology/Hematology, 2007, 63, 1-11.	4.4	28
26	First-line hysterectomy for women with low-risk non-metastatic gestational trophoblastic neoplasia no longer wishing to conceive. Gynecologic Oncology, 2018, 150, 282-287.	1.4	28
27	Efficacy and Safety of Second-Line 5-Day Dactinomycin in Case of Methotrexate Failure for Gestational Trophoblastic Neoplasia. International Journal of Gynecological Cancer, 2018, 28, 1038-1044.	2.5	27
28	A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies. Investigational New Drugs, 2011, 29, 996-1003.	2.6	24
29	Theoretical investigation of the efficacy of antiangiogenic drugs combined to chemotherapy in xenografted mice. Journal of Theoretical Biology, 2013, 320, 86-99.	1.7	21
30	Dynamic modeling in ovarian cancer: An original approach linking early changes in modeled longitudinal CA-125 kinetics and survival to help decisions in early drug development. Gynecologic Oncology, 2014, 133, 460-466.	1.4	21
31	Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patients. Breast Cancer Research and Treatment, 2016, 156, 331-341.	2.5	21
32	Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7). JNCI Cancer Spectrum, 2020, 4, pkaa026.	2.9	21
33	The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas. Cancer Treatment Reviews, 2021, 100, 102294.	7.7	21
34	Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors. European Journal of Cancer, 2022, 166, 87-99.	2.8	21
35	Computational analysis of the influence of the microenvironment on carcinogenesis. Mathematical Biosciences, 2011, 229, 22-29.	1.9	20
36	Adherence to oral anticancer chemotherapy: What influences patients' over or non-adherence? Analysis of the OCTO study through quantitative–qualitative methods. BMC Research Notes, 2015, 8, 291	1.4	20

#	Article	IF	CITATIONS
37	Clinical efficacy of the optimal biological dose in early-phase trials of anti-cancer targeted therapies. European Journal of Cancer, 2019, 120, 40-46.	2.8	19
38	Over-adherence to capecitabine: a potential safety issue in breast and colorectal cancer patients. Cancer Chemotherapy and Pharmacology, 2018, 82, 319-327.	2.3	16
39	The Increasing Prognostic and Predictive Roles of the Tumor Primary Chemosensitivity Assessed by CA-125 Elimination Rate Constant K (KELIM) in Ovarian Cancer: A Narrative Review. Cancers, 2022, 14, 98.	3.7	16
40	Prognostic value of modeled PSA clearance on biochemical relapse free survival after radical prostatectomy. Prostate, 2009, 69, 1325-1333.	2.3	14
41	Administration of Anticancer Drugs: Exposure in Hospital Nurses. Clinical Therapeutics, 2014, 36, 401-407.	2.5	14
42	Exposure-Effect Population Model of Inolimomab, a Monoclonal Antibody Administered in First-Line Treatment for Acute Graft-Versus-Host Disease. Clinical Pharmacokinetics, 2007, 46, 417-432.	3.5	13
43	Advantages of prostate-specific antigen (PSA) clearance model over simple PSA half-life computation to describe PSA decrease after prostate adenomectomy. Clinical Biochemistry, 2008, 41, 785-795.	1.9	13
44	Predictive Value of Modeled AUCAFP-hCG, a Dynamic Kinetic Parameter Characterizing Serum Tumor Marker Decline in Patients With Nonseminomatous Germ Cell Tumor. Urology, 2010, 76, 423-429.e2.	1.0	13
45	Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment. Journal of Pharmacology and Experimental Therapeutics, 2019, 369, 291-299.	2.5	13
46	Changes in the Use of Comprehensive Geriatric Assessment in Clinical Trials for Older Patients with Cancer over Time. Oncologist, 2019, 24, 1089-1094.	3.7	13
47	Using Breast Cancer Gene Expression Signatures in Clinical Practice: Unsolved Issues, Ongoing Trials and Future Perspectives. Cancers, 2021, 13, 4840.	3.7	13
48	Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme. European Journal of Cancer, 2019, 118, 156-165.	2.8	11
49	Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study). Gynecologic Oncology, 2020, 159, 256-263.	1.4	11
50	Appendiceal tumors and pseudomyxoma peritonei: French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (RENAPE, RENAPATH, SNFGE, FFCD, GERCOR, UNICANCER, SFCD,) Tj ETQo	0 0 0. øgBT	/Ouerlock 10
51	A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI – GINECO study. Gynecologic Oncology, 2022, 165, 30-39.	1.4	11
52	Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation. Cancer Chemotherapy and Pharmacology, 2012, 69, 447-455.	2.3	10
53	First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study. Breast, 2020, 54, 256-263.	2.2	10
54	Front-Line Maintenance Therapy in Advanced Ovarian Cancer—Current Advances and Perspectives. Cancers, 2020, 12, 2414.	3.7	10

#	Article	IF	CITATIONS
55	Concomitant drugs with low risks of drug–drug interactions for use in oncology clinical trials. Critical Reviews in Oncology/Hematology, 2015, 94, 189-200.	4.4	9
56	Transcriptomic and immunohistochemical approaches identify HLA-G as a predictive biomarker of gestational choriocarcinoma resistance to monochemotherapy. Gynecologic Oncology, 2020, 158, 785-793.	1.4	9
57	Influence of statistician involvement on reporting of randomized clinical trials in medical oncology. Anti-Cancer Drugs, 2013, 24, 306-309.	1.4	8
58	Open-label uncontrolled pilot study to evaluate complementary therapy with Ruta graveolens 9c in patients with advanced cancer. Homeopathy, 2014, 103, 232-238.	1.0	8
59	Differential benefit from fractionated dose-dense first-line chemotherapy for epithelial ovarian cancer (EOC) according to KELIM-evaluated tumor primary chemosensitivity: Exploratory analyses of ICON-8 trial Journal of Clinical Oncology, 2021, 39, 5530-5530.	1.6	8
60	PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers. Cancers, 2022, 14, 599.	3.7	8
61	Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA). Cancer Chemotherapy and Pharmacology, 2015, 76, 939-948.	2.3	7
62	Are Older Patients with Cervical Cancer Managed Differently to Younger Patients? An International Survey. Cancers, 2019, 11, 1955.	3.7	7
63	Validation of the Predictive Value of Modeled Human Chorionic Gonadotrophin Residual Production in Low-Risk Gestational Trophoblastic Neoplasia Patients Treated in NRG Oncology/Gynecologic Oncology Group–174 Phase III Trial. International Journal of Gynecological Cancer, 2016, 26, 208-215.	2.5	5
64	EVESOR, a model-based, multiparameter, Phase I trial to optimize the benefit/toxicity ratio of everolimus and sorafenib. Future Oncology, 2017, 13, 679-693.	2.4	5
65	Gestational trophoblastic neoplasia after human chorionic gonadotropin normalization in a retrospective cohort of 7761 patients in France. American Journal of Obstetrics and Gynecology, 2021, 225, 401.e1-401.e9.	1.3	5
66	Modeling CA-125 During Neoadjuvant Chemotherapy for Predicting Optimal Cytoreduction and Relapse Risk in Ovarian Cancer. Anticancer Research, 2017, 37, 6879-6886.	1.1	5
67	Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era. British Journal of Cancer, 2022, 127, 79-83.	6.4	5
68	Aggregated adverse-events outcomes in oncology phase III reports: A systematic review. European Journal of Cancer, 2016, 52, 26-32.	2.8	4
69	Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial. Gynecologic Oncology, 2019, 152, 68-75.	1.4	4
70	Validation of an online tool for early prediction of the failure-risk in gestational trophoblastic neoplasia patients treated with methotrexate. Cancer Chemotherapy and Pharmacology, 2020, 86, 15-24.	2.3	3
71	Independent confirmation of the strong early predictive value of modeled PSA clearance in prostate cancer patients treated by radical prostatectomy: Results of the prospective PSAMODEL study Journal of Clinical Oncology, 2012, 30, e15182-e15182.	1.6	3
72	Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program. Cancers, 2022, 14, 660.	3.7	3

#	Article	IF	CITATIONS
73	Modeled Early Longitudinal PSA Kinetics Prognostic Value in Rising PSA Prostate Cancer Patients after Local Therapy Treated with ADT +/â^ Docetaxel. Cancers, 2022, 14, 815.	3.7	3
74	Predominance of BRCA2 Mutation and Estrogen Receptor Positivity in Unselected Breast Cancer with BRCA1 or BRCA2 Mutation. Cancers, 2022, 14, 3266.	3.7	3
75	Identification of Most Aggressive Carcinoma Among Patients Diagnosed With Prostate Cancer Using Mathematical Modeling of Prostate-Specific Antigen Increases. Clinical Genitourinary Cancer, 2016, 14, 210-217.e1.	1.9	2
76	Impact of the First Wave of the COVID-19 Pandemic on the Lyon University Hospital Cancer Institute (IC-HCL). Cancers, 2022, 14, 29.	3.7	2
77	Pure Seminoma and Concurrent Aggressive Lymphoma: Case Report of a Patient With Persistent Müllerian Duct Syndrome. Clinical Genitourinary Cancer, 2019, 17, e369-e371.	1.9	1
78	Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach. Cancer Chemotherapy and Pharmacology, 2022, 89, 197-208.	2.3	1
79	<i>In Silico</i> Evaluation of Pharmacokinetic Optimization for Antimitogram-Based Clinical Trials. Cancer Research, 2018, 78, 1873-1882.	0.9	0
80	The Prognostic Value of the CA-125 Elimination Rate (KELIM) as an Indicator of Response During Neo-Adjuvant Chemotherapy in Advanced-Stage Ovarian Cancer. SSRN Electronic Journal, 0, , .	0.4	0
81	Reply to J. R. Lurain et al. Journal of Clinical Oncology, 2020, 38, 4350-4351.	1.6	0